SB 13 (see companion bill HB 1713) – Oklahoma

Status: In Process
Year Introduced: 2023
Link: http://www.oklegislature.gov/BillInfo.aspx?Bill=SB13&Session=2300

prohibits any pharmaceutical drug plan or pharmacy benefits manager from refusing to approve, pay, or authorize the dispensation of a white bagged drug to a patient solely because the drug is a white bagged drug. Additionally, the measure prohibits any health benefit plan from refusing to authorize, approve, or pay a participating provider for providing covered physicianadministered drugs to covered persons. Providers and health care facilities shall be permitted to dispense and administer a covered physician-administered drug based on a patient’s best interest if the health care facility or provider that administers the drug shall agree to the terms and conditions of network participation and accept, as payment in full, reimbursement for the drug at the health insurer’s or pharmacy benefits manager’s negotiated contracted rate. Such entities are prohibited from refusing to authorize, approve, or pay a participating provider for providing covered physician-administered drugs to covered persons. The measure also requires all white bagged drugs to meet supply chain security controls as provided in the federal Drug Supply Chain Security Act. Any entity that violates the provisions of this measure shall be fined $5,000.00-$10,000.00 per violation. Health care providers are provided with immunity from civil liability for any loss or harm to a person due to his or her health insurance plan utilizing white bagged drugs.

Return to Database Search

© 2018- The SLIHCQ DatabaseInitial funding for this project was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.

Associated Litigation:

No items found